Biotech Synergy deal

Biotech Synergy acquired cancer candidate EP-2101 from an undisclosed company. The vaccine containing nine cytotoxic T lymphocyte epitopes from four tumor associated antigens (TAA) has completed a Phase II trial in non-small cell lung cancer (NSCLC). The company is actively seeking a partner to conduct a Phase III trial of EP-2101 in the indication. Further terms were not disclosed. ...